Shailesh Vinayak Shrikhande
Shailesh Vinayak Shrikhande publishes mostly in Oncology, Surgery and Pulmonary and Respiratory Medicine, on topics such as Pancreatic and Hepatic Oncology Research, Pancreatitis Pathology and Treatment and Cholangiocarcinoma and Gallbladder Cancer Studies.
- World rank
- #709,846 of 7,710,434 ranked researchers
- Rank in India
- #9,121 of 280,097
- Works
- 454
- Citations
- 17k
- Citations per work
- 38.4
What does Shailesh Vinayak Shrikhande research?
Shailesh Vinayak Shrikhande's work is mostly in Medicine (81%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences36780.8%
- Medicine36780.8%
- Everything else8719.2%
- 1Oncology26% of their works
- 2Surgery26% of their works
- 3Pulmonary and Respiratory Medicine16% of their works
- 4Epidemiology6% of their works
- 5Gastroenterology4% of their works
- 6Hepatology3% of their works
Research topics
- Pancreatic and Hepatic Oncology Research
- Pancreatitis Pathology and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gallbladder and Bile Duct Disorders
- Gastric Cancer Management and Outcomes
- Neuroendocrine Tumor Research Advances
- Gastrointestinal Tumor Research and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
Which keywords describe Shailesh Vinayak Shrikhande's research?
The keywords of their largest research topics: Chemotherapy, Pancreatic Cancer, Surgical Complications, Epidemiology, Cholangiocarcinoma, Prognostic Factors, Surgical Management and Survival Analysis.
- Hepatocellular Carcinoma
- Imatinib Mesylate
- Neuroendocrine Tumors
- Endoscopic Resection
- Cholecystitis
- Biliary Tract Cancer
- Chronic Pancreatitis
- Survival Analysis
- Prognostic Factors
- Epidemiology
- Pancreatic Cancer
- Chemotherapy
- Surgical Complications
- Cholangiocarcinoma
- Surgical Management
- Acute Pancreatitis
- Clinical Practice Guidelines
- Intrahepatic Cholangiocarcinoma
- ERCP
- Gastric Cancer
- Pancreatic Neuroendocrine Tumors
- Sunitinib
- Liver Cancer
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 23 words, with their numbers
- Chemotherapy2802 topics
- Pancreatic Cancer2141 topic
- Surgical Complications2141 topic
- Epidemiology1842 topics
- Cholangiocarcinoma1672 topics
- Prognostic Factors1362 topics
- Surgical Management1362 topics
- Survival Analysis1262 topics
- Acute Pancreatitis961 topic
- Chronic Pancreatitis961 topic
- Clinical Practice Guidelines962 topics
- Biliary Tract Cancer881 topic
- Intrahepatic Cholangiocarcinoma881 topic
- Cholecystitis791 topic
- ERCP791 topic
- Endoscopic Resection661 topic
- Gastric Cancer661 topic
- Neuroendocrine Tumors601 topic
- Pancreatic Neuroendocrine Tumors601 topic
- Imatinib Mesylate481 topic
- Sunitinib481 topic
- Hepatocellular Carcinoma301 topic
- Liver Cancer301 topic
Where does Shailesh Vinayak Shrikhande work?
Shailesh Vinayak Shrikhande's main affiliation in the publication record is Tata Memorial Hospital, India.
How many publications and citations does Shailesh Vinayak Shrikhande have?
OpenAlex counts 454 works and 17,446 citations for Shailesh Vinayak Shrikhande, an h-index of 55, ranking #709,846 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Shailesh Vinayak Shrikhande. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.